-
Je něco špatně v tomto záznamu ?
The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers
A. Tylki-Szymańska, Z. Almássy, V. Christophidou-Anastasiadou, D. Avdjieva-Tzavella, I. Barisic, R. Cerkauskiene, G. Cuturilo, M. Djiordjevic, Z. Gucev, A. Hlavata, B. Kieć-Wilk, M. Magner, I. Pecin, V. Plaiasu, M. Samardzic, D. Zafeiriou, I....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
BioMedCentral
od 2006-01-12
BioMedCentral Open Access
od 2006
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
Springer Nature OA/Free Journals
od 2006-12-01
- MeSH
- dospělí MeSH
- enzymová substituční terapie metody MeSH
- kvalita života MeSH
- lidé MeSH
- mukopolysacharidóza II * farmakoterapie MeSH
- mukopolysacharidóza IV * farmakoterapie MeSH
- mukopolysacharidózy * farmakoterapie terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by defects in genes coding for different lysosomal enzymes which degrade glycosaminoglycans. Impaired lysosomal degradation causes cell dysfunction leading to progressive multiorgan involvement, disabling consequences and poor life expectancy. Enzyme replacement therapy (ERT) is now available for most MPS types, offering beneficial effects on disease progression and improving quality of life of patients. The landscape of MPS in Europe is not completely described and studies on availability of treatment show that ERT is not adequately implemented, particularly in Southern and Eastern Europe. In this study we performed a survey analysis in main specialist centers in Southern and Eastern European countries, to outline the picture of disease management in the region and understand ERT implementation. Since the considerable number of MPS IVA patients in the region, particularly adults, the study mainly focused on MPS IVA management and treatment. RESULTS: 19 experts from 14 Southern and Eastern European countries in total responded to the survey. Results outlined a picture of MPS management in the region, with a high number of MPS patients managed in the centers and a high level of care. MPS II was the most prevalent followed by MPS IVA, with a particular high number of adult patients. The study particularly focused on management and treatment of MPS IVA patients. Adherence to current European Guidelines for follow-up of MPS IVA patients is generally adequate, although some important assessments are reported as difficult due to the lack of MPS skilled specialists. Availability of ERT in Southern and Eastern European countries is generally in line with other European regions, even though regulatory, organizational and reimbursement constrains are demanding. CONCLUSIONS: The landscape of MPS in Southern and Eastern European countries is generally comparable to that of other European regions, regarding epidemiology, treatment accessibility and follow up difficulties. However, issues limiting ERT availability and reimbursement should be simplified, to start treatment as early as possible and make it available for more patients. Besides, educational programs dedicated to specialists should be implemented, particularly for pediatricians, clinical geneticists, surgeons, anesthesiologists and neurologists.
1st Department of Pediatrics Hippokratio General Hospital Aristotle University Thessaloniki Greece
Archbishop Makarios 3 Hospital Nicosia Cyprus
Department of Clinical Genetics University Pediatric Hospital Sofia Bulgaria
Faculty of Medicine University of Belgrade Belgrade Serbia
Mother and Child Health Care Institute of Serbia Medical University of Belgrade Belgrade Serbia
Regional Centre of Medical Genetics INSMC Alessandrescu Rusescu Bucharest Romania
University Children's Hospital Belgrade Serbia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019133
- 003
- CZ-PrNML
- 005
- 20220804135400.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13023-022-02285-x $2 doi
- 035 __
- $a (PubMed)35331284
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Tylki-Szymańska, Anna $u Department of Pediatric Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland
- 245 14
- $a The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers / $c A. Tylki-Szymańska, Z. Almássy, V. Christophidou-Anastasiadou, D. Avdjieva-Tzavella, I. Barisic, R. Cerkauskiene, G. Cuturilo, M. Djiordjevic, Z. Gucev, A. Hlavata, B. Kieć-Wilk, M. Magner, I. Pecin, V. Plaiasu, M. Samardzic, D. Zafeiriou, I. Zaganas, C. Lampe
- 520 9_
- $a BACKGROUND: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by defects in genes coding for different lysosomal enzymes which degrade glycosaminoglycans. Impaired lysosomal degradation causes cell dysfunction leading to progressive multiorgan involvement, disabling consequences and poor life expectancy. Enzyme replacement therapy (ERT) is now available for most MPS types, offering beneficial effects on disease progression and improving quality of life of patients. The landscape of MPS in Europe is not completely described and studies on availability of treatment show that ERT is not adequately implemented, particularly in Southern and Eastern Europe. In this study we performed a survey analysis in main specialist centers in Southern and Eastern European countries, to outline the picture of disease management in the region and understand ERT implementation. Since the considerable number of MPS IVA patients in the region, particularly adults, the study mainly focused on MPS IVA management and treatment. RESULTS: 19 experts from 14 Southern and Eastern European countries in total responded to the survey. Results outlined a picture of MPS management in the region, with a high number of MPS patients managed in the centers and a high level of care. MPS II was the most prevalent followed by MPS IVA, with a particular high number of adult patients. The study particularly focused on management and treatment of MPS IVA patients. Adherence to current European Guidelines for follow-up of MPS IVA patients is generally adequate, although some important assessments are reported as difficult due to the lack of MPS skilled specialists. Availability of ERT in Southern and Eastern European countries is generally in line with other European regions, even though regulatory, organizational and reimbursement constrains are demanding. CONCLUSIONS: The landscape of MPS in Southern and Eastern European countries is generally comparable to that of other European regions, regarding epidemiology, treatment accessibility and follow up difficulties. However, issues limiting ERT availability and reimbursement should be simplified, to start treatment as early as possible and make it available for more patients. Besides, educational programs dedicated to specialists should be implemented, particularly for pediatricians, clinical geneticists, surgeons, anesthesiologists and neurologists.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a enzymová substituční terapie $x metody $7 D056947
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mukopolysacharidózy $x farmakoterapie $x terapie $7 D009083
- 650 12
- $a mukopolysacharidóza II $x farmakoterapie $7 D016532
- 650 12
- $a mukopolysacharidóza IV $x farmakoterapie $7 D009085
- 650 _2
- $a kvalita života $7 D011788
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Almássy, Zsuzsanna $u Department of Toxicology and Metabolic Diseases, Heim Pal Children's Hospital Budapest, Budapest, Hungary
- 700 1_
- $a Christophidou-Anastasiadou, Violetta $u Archbishop Makarios III Hospital, Nicosia, Cyprus
- 700 1_
- $a Avdjieva-Tzavella, Daniela $u Department of Clinical Genetics, University Pediatric Hospital, Sofia, Bulgaria
- 700 1_
- $a Barisic, Ingeborg $u Centre of Excellence for Reproductive and Regenerative Medicine, Children's Hospital Zagreb, Medical School University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Cerkauskiene, Rimante $u Clinic of Paediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- 700 1_
- $a Cuturilo, Goran $u Faculty of Medicine, University of Belgrade, Belgrade, Serbia $u University Children's Hospital, Belgrade, Serbia
- 700 1_
- $a Djiordjevic, Maja $u Mother and Child Health Care Institute of Serbia, Medical University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Gucev, Zoran $u University Children's Hospital, Skopje, North Macedonia
- 700 1_
- $a Hlavata, Anna $u National Institute of Children's Diseases, Department of Paediatrics, Medical Faculty Comenius University, Centre for Inherited Metabolic Disorders, Bratislava, Slovakia
- 700 1_
- $a Kieć-Wilk, Beata $u Unit of Rare Metabolic Diseases, Department of Metabolic Diseases, Jagiellonian University Medical College, University Hospital, Krakow, Poland
- 700 1_
- $a Magner, Martin $u Department of Paediatrics, University Thomayer Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Pediatrics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Pecin, Ivan $u University Hospital Centre Zagreb, Department of Internal Medicine, Division of Metabolic Diseases, Zagreb School of Medicine, Zagreb, Croatia
- 700 1_
- $a Plaiasu, Vasilica $u Regional Centre of Medical Genetics, INSMC Alessandrescu-Rusescu, Bucharest, Romania
- 700 1_
- $a Samardzic, Mira $u Institute for Sick Children, Department of Pediatric Endocrinology and Metabolism, Medical School, University of Montenegro, Podgorica, Montenegro
- 700 1_
- $a Zafeiriou, Dimitrios $u First Department of Pediatrics, Hippokratio General Hospital, Aristotle University, Thessaloniki, Greece
- 700 1_
- $a Zaganas, Ioannis $u Neurogenetics Laboratory, Neurology Department, University Hospital of Heraklion, University of Crete, Heraklion, Greece
- 700 1_
- $a Lampe, Christina $u Department of Child Neurology, Epileptology and Social Pediatrics, Centre for Rare Diseases, University of Giessen, Standort Giessen, Feulgenstr. 12, 35389, Giessen, Germany. christina.lampe@paediat.med.uni-giessen.de $1 https://orcid.org/0000000255290506
- 773 0_
- $w MED00165365 $t Orphanet journal of rare diseases $x 1750-1172 $g Roč. 17, č. 1 (2022), s. 136
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35331284 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135354 $b ABA008
- 999 __
- $a ok $b bmc $g 1822650 $s 1170376
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 17 $c 1 $d 136 $e 20220324 $i 1750-1172 $m Orphanet journal of rare diseases $n Orphanet J Rare Dis $x MED00165365
- LZP __
- $a Pubmed-20220720
